A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)
Phase 2
130
about 6.3 years
18+
12 sites in AK, ID, MA +7
What this study is about
This trial is testing a treatment called BMS-986504 for people with advanced lung cancer that has not responded to other treatments. The goal is to see if BMS-986504 can help improve the lives of these patients.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take BMS-986504
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Number of participants who achieve Objective Response (OR) utilizing the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Secondary: Change from baseline in cancer-related symptoms and health-related quality of life as assessed by the EORTC-QLQ-F17 quality-of-life (QoL) functional scale score, Change from baseline in cancer-related symptoms and health-related quality of life as assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core Function Global Health Status functional scale score, Change from baseline in cancer-related symptoms and health-related quality of life as assessed by the Non-small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) total score and symptom score, Duration of response (DOR) as assessed by RECIST v1.1, Number of deaths, Number of participants who achieve Objective Response (OR) as assessed by RECIST v1.1, Number of participants with AEs leading to dose interruption, reduction, or discontinuation, Number of participants with Serious AEs (SAEs)
Oncology